How Much Did Rectify Pharmaceuticals Raise?
Funding & Key Investors

Rectify Pharmaceuticals has secured $100M in total funding, with its most recent capital infusion of $100M described as a major strategic investment. This significant backing underscores the company's progress in developing novel therapeutics.

What is Rectify Pharmaceuticals?

Rectify Pharmaceuticals
ManufacturingPharmaceuticalsBusiness Services

Rectify Pharmaceuticals, a biotechnology firm headquartered in Cambridge, MA, is dedicated to pioneering Positive Functional Modulators (PFMs). These disease-modifying precision therapeutics are engineered to restore ABC transporter function, offering a new therapeutic avenue for patients afflicted with serious genetic diseases. The company's focus on genetic disorders positions it within a critical and rapidly advancing segment of the pharmaceutical industry.

How much funding has Rectify Pharmaceuticals raised?

Rectify Pharmaceuticals has raised a total of $100M across 1 funding round:

2021

Series A

$100M

Series A (2021): $100M with participation from Omega Fund Management, Forbion, and Atlas Venture

Key Investors in Rectify Pharmaceuticals

Omega Fund Management

Omega Fund Management is an investment firm with a strong focus on drug discovery and development companies within the life science and healthcare sectors. Their expertise spans private equity investing and strategic consulting.

Forbion

Forbion is a leading European venture capital firm specializing in bridging research and development in the life sciences, leveraging deep expertise in drug development and company building. They are committed to responsible investment principles.

Atlas Venture

Atlas Venture is a venture capital firm focused on creating and building early-stage biotechnology companies. They partner with entrepreneurs to translate cutting-edge science into life-changing medicines.

What's next for Rectify Pharmaceuticals?

The substantial enterprise-level funding, particularly the recent strategic investment, suggests Rectify Pharmaceuticals is poised for significant scaling and advancement of its PFM pipeline. This capital infusion will likely accelerate clinical development, expand research initiatives, and potentially facilitate strategic partnerships. The company's trajectory indicates a move towards later-stage development, aiming to bring its innovative treatments to patients in need.

See full Rectify Pharmaceuticals company page
See More Financial Insights
No matching results.
Refine your search.

Additional financial insights in the Manufacturing industry

Industrial Machinery & EquipmentManufacturing
ManufacturingTelecommunication Equipment
Industrial Machinery & EquipmentManufacturingArchitecture, Engineering & DesignConstruction
Building MaterialsManufacturing

Frequently Asked Questions Regarding Rectify Pharmaceuticals Financial Insights

What are the most recent funding rounds that Rectify Pharmaceuticals has completed, and what were the funding rounds?
Rectify Pharmaceuticals has recently completed 1 funding rounds: Series A on Oct 14, 2021.
What is the total amount of funding Rectify Pharmaceuticals has raised to date?
Rectify Pharmaceuticals has raised a total of $100M in funding to date.
How many funding rounds has Rectify Pharmaceuticals completed?
Rectify Pharmaceuticals has completed 1 funding rounds.
How much funding did Rectify Pharmaceuticals raise in its most recent funding round?
Rectify Pharmaceuticals raised $100M in its most recent funding round.
Who are the lead investors in Rectify Pharmaceuticals's latest funding round?
The lead investor in Rectify Pharmaceuticals's latest funding round was Omega Fund Management. To access investor data and explore similar companies, sign up for ZoomInfo.
Which was the largest funding round in Rectify Pharmaceuticals's history?
The largest funding round in Rectify Pharmaceuticals's history was $100M.
See more information about Rectify Pharmaceuticals